Rosetta Genomics and Rockefeller University Sign MicroRNA Licensing Agreement Deal gives Rosetta Genomics access to nearly 180 proprietary microRNAs with

potential applications in the development of a range of diagnostic tools

for a variety of diseases



    REHOVOT, Israel, June 14 /PRNewswire/ -- Rosetta Genomics and
 Rockefeller University today announced the signing of a licensing agreement
 that will allow Rosetta Genomics to access nearly 180 proprietary microRNAs
 from Rockefeller University. These microRNAs will be added to Rosetta
 Genomics's microRNA database, providing the company with additional
 biomarker candidates for its diagnostic development programs. Under the
 terms of the agreement, Rosetta Genomics will be able to use these
 microRNAs to potentially advance multiple research development programs
 targeting new microRNA based diagnostic tools for a variety of diseases.
     "Being one of the first companies to focus on microRNAs, we see
 ourselves as leaders in this field, and our filed patent applications cover
 more than half of all biologically validated microRNAs of which we are
 aware. This agreement positions us to apply our experience and expand our
 development program further in the years ahead. We are now positioned to
 target a broader range of promising development and commercial
 opportunities in the microRNA arena," said Amir Avniel, president and CEO
 of Rosetta Genomics.
     Rosetta Genomics has developed a proprietary discovery process that has
 led to the discovery of nearly 360 biologically validated human microRNAs.
 The agreement with Rockefeller positions Rosetta Genomics to pursue
 research based on 530 of the 660 publicly-confirmed microRNA genes in the
 entire human genome. Under the terms of the agreement, Rosetta Genomics
 will pay an initiation fee to Rockefeller University as well as maintenance
 fees and royalties.
     About microRNAs
     MicroRNAs (miRNAs) are recently discovered, naturally occurring small
 RNAs that act as protein regulators and have the potential to be the basis
 for a new class of diagnostics and therapeutics. Because many diseases are
 caused by the misregulated activity of proteins, the ability to selectively
 regulate protein activity through microRNAs could provide the means to
 treat a wide range of human diseases. In addition, microRNAs have been
 shown to have different expression levels in certain diseased versus normal
 tissues. These differences potentially provide for a novel diagnostic
 strategy for many diseases. MicroRNAs are thought to play a key role in the
 differentiation of cells into specific cell types performing various
 functions in the body. The recent discovery of microRNAs is recognized as a
 major scientific breakthrough that has the potential to transform the
 diagnosis, prevention and treatment of diseases.
     About Rockefeller University
     The Rockefeller University is a world-renowned center for research and
 graduate education in the biomedical sciences, chemistry, and physics.
 Founded by John D. Rockefeller in 1901, the university has been the site of
 many important scientific breakthroughs. Rockefeller scientists established
 that DNA is the chemical basis of heredity, discovered blood groups, showed
 that viruses can cause cancer, founded the modern field of cell biology,
 and worked out the structure of antibodies. Twenty-three Nobel Prize
 winners have been associated with the university.
     For more information please visit: http://www.rockefeller.edu
     About Rosetta Genomics
     Rosetta Genomics is a leader in the development of microRNA-based
 diagnostics and therapeutics. Founded in 2000, the company's integrative
 research platform combining bioinformatics and state-of-the-art laboratory
 processes has led to the discovery of nearly 360 biologically validated
 novel human microRNAs. Building on its strong IP position and strategic
 alliances with leading biotechnology companies, Rosetta Genomics is working
 to develop a full range of diagnostics and therapeutic products based on
 microRNAs. The company's primary therapeutic focus is in the development of
 microRNA-based products to diagnose and treat different forms of cancer.
 
 

SOURCE Rosetta Genomics

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.